How Asian markets are responding to the coronavirus outbreak

Did BioNTech Stock Rise Too Far, Too Fast, on Coronavirus Vaccine News?

Coronavirus is a global pandemic. With nearly 220,000 patients infected with COVID-19 at last report (according to Johns Hopkins University data), the populations of 158 countries affected, and casualties exceeding 8,800 souls, this is a problem for all the world -- and it's pulling in companies from all around the world to try to solve it.Case in point: One of the companies leading the effort to rapidly develop a vaccine against the novel coronavirus is Germany's BioNTech SE (BNTX).Two days ago, BioNTech announced that it will partner with American pharmaceuticals giant Pfizer to develop the German company's mRNA-based vaccine candidate BNT162 to prevent COVID-19 infection."Leveraging expertise and resources of both companies" said BioNTech and Pfizer in a statement, the "collaboration aims to accelerate global development of BNT162," with cooperation beginning immediately, and clinical testing to begin in late April 2020. From start of testing to eventual approval (one hopes), could take...